{"id":2351,"date":"2017-10-03T17:47:50","date_gmt":"2017-10-03T12:17:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2351"},"modified":"2021-07-24T12:56:51","modified_gmt":"2021-07-24T07:26:51","slug":"notizia-53","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-53","title":{"rendered":"Therapeutics and Celgene to develop therapies; Takeda\u2019s expansion; J&#038;J hopes to limit; Tech Prize for genome sequencing; Endocyte\u2019s late-stage prostate cancer deal"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a4246a3646dc\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a4246a3646dc\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-53\/#Strategic_Immunology_Alliance_partners_Nimbus_Therapeutics_and_Celgene_to_develop_therapies_for_Autoimmune_Disorders\" >Strategic Immunology Alliance partners Nimbus Therapeutics and Celgene to develop therapies for Autoimmune Disorders<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-53\/#Takeda_is_expanding_its_EU_presence_while_AZ_is_thinking_to_pull_out_from_the_UK\" >Takeda is expanding its EU presence while AZ is thinking to pull out from the UK<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-53\/#J_J_hopes_to_limit_Invokana_damage_through_FDA_cardio_label\" >J&amp;J hopes to limit Invokana damage through FDA cardio label<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-53\/#Tech_Prize_for_a_company_that_includes_genome_sequencing_for_prescribing_antibiotics\" >Tech Prize for a company that includes genome sequencing for prescribing antibiotics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-53\/#Endocyte_gets_back_on_track_with_a_late-stage_prostate_cancer_deal\" >Endocyte gets back on track with a late-stage prostate cancer deal<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Strategic_Immunology_Alliance_partners_Nimbus_Therapeutics_and_Celgene_to_develop_therapies_for_Autoimmune_Disorders\"><\/span>Strategic Immunology Alliance partners Nimbus Therapeutics and Celgene to develop therapies for Autoimmune Disorders<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering into a long-term strategic alliance with Celgene Corporation in the therapy area of immunology. The terms of the agreement will help Celgene use the option to acquire each program in the alliance up through a clinical inflection point. In turn, Nimbus will receive an upfront payment and potential downstream milestone payments for each program Celgene chooses to acquire. As for the R&amp;D activities, Nimbus will retain full control of each program until the option is exercised by Celgene. The financial terms of each program are said to remain undisclosed until Celgene acquires one.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Takeda_is_expanding_its_EU_presence_while_AZ_is_thinking_to_pull_out_from_the_UK\"><\/span>Takeda is expanding its EU presence while AZ is thinking to pull out from the UK<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Brexit has impacted many developmental and investment activities in the country, but this has not deterred Takeda in wanting to invest in the area of production operation in the EU. The company is in talks to invest around \u20ac100 million in developing a manufacturing plant near Dublin, Ireland. This move might eventually lead to adding up to 100 jobs in that territory. On the other hand, however, UK based AstraZeneca might be on the verge of pulling out some manufacturing and research operations from the U.K. if there is not a viable deal for its exit from the European Union.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"J_J_hopes_to_limit_Invokana_damage_through_FDA_cardio_label\"><\/span>J&amp;J hopes to limit Invokana damage through FDA cardio label<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The diabetes drug of Johnson &amp; Johnson, Invokana, has been seen to increase the risk of lower limb amputations, which steeply declined the 2<sup>nd<\/sup> quarters&#8217; sales of the drug, leading the company to move ahead to limit the damage with some good news for the drug. The CANVAS trial results, which came out in June 2017, show that Invokana (canagliflozin) is able to reduce the risk of major adverse cardiovascular events (CVAEs) in high-risk adults compared with placebo. Due to the amputation risk, J&amp;J had to include a very serious \u201cblack box\u201d safety alert on Invokana\u2019s label, but the company hopes to salvage some sales by updating the label with the good results related to CVAEs.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Tech_Prize_for_a_company_that_includes_genome_sequencing_for_prescribing_antibiotics\"><\/span>Tech Prize for a company that includes genome sequencing for prescribing antibiotics<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Day Zero Diagnostics, a Massachusetts-based AI company, grabbed the top spot in 2017 MedTech Innovator Global Competition, by beating almost 600 other companies to win a handsome grand prize of $350,000. The prize was awarded to this company based on their AI platform that analyzes individual patient genomic data to help doctors prescribe antibiotics, and thus bypass the broad spectrum antibiotic treatment plan to treat infections, and restrict the chances of formation of superbugs. The technology also combines the individual patient results with insights from big data sources, so that more targeted regimens of antibiotics can emerge to treat infections and help decrease recovery time and lower treatment costs.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Endocyte_gets_back_on_track_with_a_late-stage_prostate_cancer_deal\"><\/span>Endocyte gets back on track with a late-stage prostate cancer deal<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Endocyte received an exclusive worldwide license for German biotech ABX\u2019s phase 3-ready prostate cancer candidate 177Lu-PSMA-617, leading to a great surge in its stock price. The stock price rose by almost 150%, as the deal foresees a drug approval in a few years. The drug candidate is a radioligand therapeutic (RLT), which is a potent target to the prostate-specific membrane antigen (PSMA), Ths PSMA is an antigen that has been observed to be present in around 80% of patients with metastatic castration-resistant prostate cancer (mCRPC). This deal is being viewed as a fortune turner for Endocyte, whose own PSMA drug had failed efficacy studied, as seen in negative trial results in June.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Strategic Immunology Alliance partners Nimbus Therapeutics and Celgene to develop therapies for Autoimmune Disorders A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering into a long-term strategic alliance with Celgene Corporation in the therapy area of immunology. The terms of the agreement [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1712,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1856,96,155,1069,704,921,420,730,712,639,702,5789,1067,554,1068],"industry":[17225],"therapeutic_areas":[17240,17227],"class_list":["post-2351","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers","tag-astrazeneca","tag-celgene","tag-endocyte","tag-fda","tag-jj","tag-news","tag-notizia","tag-pharma-industry","tag-pharma-news","tag-rd","tag-recent-pharma-news","tag-sunny-pharmtech","tag-takeda","tag-vitruvias-therapeutics","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Therapeutics and Celgene to develop therapies; Takeda\u2019s expansion<\/title>\n<meta name=\"description\" content=\"A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-53\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapeutics and Celgene to develop therapies; Takeda\u2019s expansion\" \/>\n<meta property=\"og:description\" content=\"A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-53\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-10-03T12:17:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"343\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Therapeutics and Celgene to develop therapies; Takeda\u2019s expansion","description":"A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-53","og_locale":"en_US","og_type":"article","og_title":"Therapeutics and Celgene to develop therapies; Takeda\u2019s expansion","og_description":"A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-53","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-10-03T12:17:50+00:00","article_modified_time":"2021-07-24T07:26:51+00:00","og_image":[{"width":960,"height":343,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-53","url":"https:\/\/www.delveinsight.com\/blog\/notizia-53","name":"Therapeutics and Celgene to develop therapies; Takeda\u2019s expansion","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-53#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-53#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","datePublished":"2017-10-03T12:17:50+00:00","dateModified":"2021-07-24T07:26:51+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-53"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-53#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","width":960,"height":343},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news-300x107.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">alzheimer&#039;s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Endocyte<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">J&amp;J<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">R&amp;D<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sunny Pharmtech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Takeda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vitruvias Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">alzheimer&#039;s<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">Endocyte<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">J&amp;J<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">R&amp;D<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Sunny Pharmtech<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>","<span class=\"advgb-post-tax-term\">Vitruvias Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 3, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 3, 2017 5:47 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2351"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2351\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1712"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2351"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2351"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}